ArticleOncology letters2012
URD12: A urea derivative with marked antitumor activities.
Article in Oncology letters, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Impact of trifluoromethyl and sulfonyl groups on the biological activity of novel aryl-urea derivatives: synthesis, in-vitro, in-silico and SAR studies.Scientific reports · 2023Article
- The Biological Roles of Urea: A Review of Preclinical Studies.Indian journal of nephrologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Urea derivatives have been widely used in biology and medicine. The substituted urea derivative URD12 introduced in this study exhibits cytotoxic activity against the K562 human leukemia and KB human mouth epidermal carcinoma cell lines. To further study the bioactivity of URD12 and examine its feasibility as a new antitumor drug, we applied in vivo and in vitro assays to investigate the antitumor activity of URD12. URD12 was prepared and its cytotoxicity was evaluated using the BGC-823 human gastric carcinoma, MGC-803 human gastric carcinoma, SMMC-7721 human hepatoma and HepG2 human hepatocellular carcinoma cell lines using MTT assays. Antitumor activity in vivo was confirmed in mice bearing H22 hepatocellular carcinoma cells. Organ coefficient was used to further elucidate the cytotoxic mechanisms of URD12. URD12 inhibited the growth of tested tumor cell lines in vitro and the growth of H22 mouse hepatocellular carcinoma in vivo with no effects on the weight, spleen and thymus coefficient of tumor-bearing mice. In conclusion, our findings indicate that URD12 is an effective antitumor agent without evident immunosuppression effects.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.